HeartFlow to Present at the Morgan Stanley Global Healthcare Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference.

HeartFlow Holding Inc.’s management is scheduled to present on Wednesday, September 15 at 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.heartflow.com/investors/. A link to the company’s investor presentation is also available at www.heartflow.com/investors/.

About the HeartFlow FFRct Analysis

Starting with a standard coronary computed tomography angiogram (CTA), the HeartFlow Analysis leverages deep learning and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRct values along the coronary arteries. This information helps physicians evaluate the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. A positive FFRct value (≤0.80) indicates that a coronary blockage is impeding blood flow to the heart muscle to a degree which may warrant invasive management.

Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow Analysis have been published in more than 425 peer-reviewed publications, including long-term data out to five years. The HeartFlow Analysis offers the highest diagnostic performance available from a non-invasive test.¹ To date, clinicians around the world have used the HeartFlow Analysis for more than 100,000 patients to aid in the diagnosis of heart disease.

About HeartFlow

HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRct Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRct Analysis is commercially available in the United States, UK, Canada, Europe and Japan. For more information, visit www.heartflow.com.

1. Driessen, R., et al. J Am Coll Cardiol. 2019;73(2),161-73.